<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1382">
  <stage>Registered</stage>
  <submitdate>7/06/2006</submitdate>
  <approvaldate>15/06/2006</approvaldate>
  <actrnumber>ACTRN12606000243516</actrnumber>
  <trial_identification>
    <studytitle>The role of novel fatty acid oxidation products in heart disease</studytitle>
    <scientifictitle>To determine whether flaxseed oil supplementation in healthy men produces novel fatty acid oxidation products in plasma and urine.</scientifictitle>
    <utrn />
    <trialacronym>Floxi</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy men</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is placebo-controlled, double-blind, of parallel design.                                                                                                                                                                                         Participants will be randomly allocated to take capsules of 9 X 1gm per day of flaxseed oil (By Nature, Perth, Western Australia), orally for 4 weeks, while maintaining their normal dietary habits and physically activity. </interventions>
    <comparator>Participants will be randomly allocated to take capsules of  9 X 1gm per day of olive oil (Cardinal Health Australia, Braeside, Victoria), orally for 4 weeks, while maintaining their normal dietary habits and physically activity.</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>This project will examine whether fatty acids that occur naturally in the diet, when consumed as flaxseed oil, are converted in the body to  novel fatty acid oxidation products known as phytoprostanes</outcome>
      <timepoint>After 4 weeks supplementation with flaxseed oil.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides.</outcome>
      <timepoint>After 4weeks supplementation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy, non-smoking, non-diabetic, not taking medication or dietary supplements.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Angina pectoris; major surgery or a cardiovascular event or diagnosis &lt;12 months; liver or kidney disease; current smokers; fasting blood triglycerides &gt;1.8 mmol/L; 2 or less fish meals per week or regularly taking fish oil capsules.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central allocation  by a statistician not involved with the trial</concealment>
    <sequence>computor generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/07/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Trevor Mori</primarysponsorname>
    <primarysponsoraddress>School of Medicine &amp; Pharmacology
GPO Box X2213
Perth WA 6847</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of Australia</fundingname>
      <fundingaddress>National Heart Foundation of Australia, Melbourne</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Anne Barden</sponsorname>
      <sponsoraddress>School of Medicine &amp; Pharmacology
GPO Box X2213
Perth WA 6847</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Kevin Croft</sponsorname>
      <sponsoraddress>School of Medicine &amp; Pharmacology
GPO Box X2213
Perth WA 6847</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The hypothesis is that fatty acids consumed in flaxseed oil are converted in the body to novel fatty acid oxidation products. The purpose of the study is to determine whether these fatty acid oxidation products can be measured in the blood and urine of men following supplementation with flaxseed oil for 4 weeks. The study subjects, the investigators and the statistical analyst are blinded to the treatment allocation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2006</ethicapprovaldate>
      <hrec>RA/4/1/1442</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Trevor Mori</name>
      <address>GPO Box X2213
Perth WA 6847</address>
      <phone>+61 8 92240273</phone>
      <fax>+61 8 92240246</fax>
      <email>tmori@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Trevor Mori</name>
      <address>GPO Box X2213
Perth WA 6847</address>
      <phone>+61 8 92240273</phone>
      <fax>+61 8 92240246</fax>
      <email>tmori@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>